Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.42 |
| ▸ | TREH | O43280 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.32 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GJA1 | P17302 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26902707 | 1.00 | LGALS3 (0.42) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL23705096 | 1.00 | LGALS3 (0.42) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL23704952 | 0.85 | LGALS3 (0.46) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL24256557 | 0.85 | LGALS3 (0.46) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL30103366 | 0.84 | LGALS3 (0.40) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL24256594 | 0.84 | LGALS3 (0.40) | LGALS3TREHSILGALS1LGALS9 | |
| SCHEMBL21425220 | 0.79 | LGALS3 (0.42) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL18270028 | 0.79 | LGALS3 (0.42) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL24916903 | 0.79 | LGALS3 (0.42) | LGALS3TREHLGALS1LGALS9LGALS8 | |
| SCHEMBL24916758 | 0.79 | LGALS3 (0.42) | LGALS3TREHLGALS1LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LGALS3 240/4885TREH 2371/4885SI 1585/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | LGALS3 304/4885TREH 3300/4885SI 1825/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LGALS3 435/4885TREH 4061/4885SI 1277/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS3 264/4885TREH 2467/4885SI 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.